- Home
- MFIN vs ENGN Comparison
MFIN vs ENGN Comparison
Compare MFIN & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- ENGN
- Stock Information
- Founded
- MFIN 1995
- ENGN 1999
- Country
- MFIN United States
- ENGN Canada
- Employees
- MFIN N/A
- ENGN N/A
- Industry
- MFIN Finance: Consumer Services
- ENGN
- Sector
- MFIN Finance
- ENGN
- Exchange
- MFIN Nasdaq
- ENGN Nasdaq
- Market Cap
- MFIN 207.3M
- ENGN 199.7M
- IPO Year
- MFIN 1996
- ENGN N/A
- Fundamental
- Price
- MFIN $9.17
- ENGN $3.84
- Analyst Decision
- MFIN
- ENGN Buy
- Analyst Count
- MFIN 0
- ENGN 7
- Target Price
- MFIN N/A
- ENGN $23.29
- AVG Volume (30 Days)
- MFIN 41.3K
- ENGN 93.7K
- Earning Date
- MFIN 07-29-2025
- ENGN 06-13-2025
- Dividend Yield
- MFIN 3.60%
- ENGN N/A
- EPS Growth
- MFIN N/A
- ENGN N/A
- EPS
- MFIN 1.60
- ENGN N/A
- Revenue
- MFIN $316,751,000.00
- ENGN N/A
- Revenue This Year
- MFIN N/A
- ENGN N/A
- Revenue Next Year
- MFIN $5.24
- ENGN N/A
- P/E Ratio
- MFIN $5.73
- ENGN N/A
- Revenue Growth
- MFIN 13.91
- ENGN N/A
- 52 Week Low
- MFIN $6.48
- ENGN $2.65
- 52 Week High
- MFIN $10.50
- ENGN $12.80
- Technical
- Relative Strength Index (RSI)
- MFIN 50.42
- ENGN 48.79
- Support Level
- MFIN $9.14
- ENGN $3.85
- Resistance Level
- MFIN $9.48
- ENGN $4.42
- Average True Range (ATR)
- MFIN 0.31
- ENGN 0.45
- MACD
- MFIN -0.02
- ENGN 0.08
- Stochastic Oscillator
- MFIN 44.83
- ENGN 65.75
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.